The FDA’s shifting goalposts on rare disease drugs

Marty Makary appeared for Thursday an interview on CNBC to tout efforts under his leadership at the Food and Drug Administration to speed up approvals for treatments of rare diseases. Instead, he wound up tanking the stock of a biotech company struggling to advance a leading-edge gene therapy drug t...

Redirecting to full article...